Calliditas Therapeutics
ISIN: SE0010441584 | Ticker: CALTX | LEI: 549300PVPZO8TNT76B58
Country: Sweden
Calliditas is dedicated to expanding treatment options and establishing new standards of care for people with rare diseases. By drawing on our expertise in pharmaceutical product development and leveraging our strategic partnerships, we quickly and efficiently identify, develop, and market a pipeline of innovative medicines that can improve the lives of patients.
Recently, we successfully commercialized our lead candidate in the United States, and in collaboration with our partners, launched in Europe, with plans to seek approval in Asia.
2004
HeadquartersKungsbron 1, 11122 Stockholm – Sweden
| Line item in (sek) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | N/A | 1,463,908,000.00 | 1,459,910,000.00 | 1,952,973,000.00 |
| Noncurrent Assets | N/A | N/A | 427,057,000.00 | 447,138,000.00 | 540,770,000.00 |
| Property Plant And Equipment | N/A | N/A | 163,000.00 | 6,309,000.00 | 7,468,000.00 |
| Current Assets | N/A | N/A | 1,036,851,000.00 | 1,012,772,000.00 | 1,412,204,000.00 |
| Inventories | N/A | N/A | 0.00 | 889,000.00 | 3,647,000.00 |
| Trade And Other Current Receivables | N/A | N/A | N/A | 0.00 | 78,703,000.00 |
| Current Prepaid Expenses | N/A | N/A | 17,746,000.00 | 45,032,000.00 | 70,741,000.00 |
| Cash and cash equivalents | 646,175,000.00 | 753,540,000.00 | 996,304,000.00 | 955,507,000.00 | 1,249,094,000.00 |
| Other Current Assets | N/A | N/A | 22,801,000.00 | 11,343,000.00 | 10,018,000.00 |
| Equity And Liabilities | N/A | N/A | 1,463,908,000.00 | 1,459,910,000.00 | 1,952,973,000.00 |
| Equity | 618,175,000.00 | 788,071,000.00 | 1,256,300,000.00 | 1,008,281,000.00 | 766,264,000.00 |
| Issued Capital | N/A | N/A | 1,998,000.00 | 2,094,000.00 | 2,383,000.00 |
| Retained Earnings | N/A | N/A | -918,596,000.00 | -1,426,574,000.00 | -1,836,317,000.00 |
| Other Reserves | N/A | N/A | -6,090,000.00 | -26,979,000.00 | 9,307,000.00 |
| Additional Paidin Capital | N/A | N/A | 2,133,179,000.00 | 2,459,741,000.00 | 2,590,890,000.00 |
| Equity Attributable To Owners Of Parent | N/A | N/A | 1,210,491,000.00 | 1,008,281,000.00 | 766,264,000.00 |
| Noncontrolling Interests | N/A | N/A | 45,809,000.00 | 0.00 | N/A |
| Noncurrent Liabilities | N/A | N/A | 101,989,000.00 | 316,183,000.00 | 861,479,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | N/A | 8,296,000.00 | 3,182,000.00 | 884,000.00 |
| Other Longterm Provisions | N/A | N/A | 6,391,000.00 | 14,530,000.00 | 11,792,000.00 |
| Noncurrent Interest Payable | N/A | N/A | 0.00 | 189,164,000.00 | 713,030,000.00 |
| Other Noncurrent Liabilities | N/A | N/A | 878,000.00 | 0.00 | 4,350,000.00 |
| Current Liabilities | N/A | N/A | 105,619,000.00 | 135,446,000.00 | 325,231,000.00 |
| Trade And Other Current Payables | N/A | N/A | 53,827,000.00 | 67,971,000.00 | 160,404,000.00 |
| Current Tax Liabilities Current | N/A | N/A | 518,000.00 | 1,221,000.00 | 5,684,000.00 |
| Current Accrued Expenses And Other Current Liabilities | N/A | N/A | N/A | 53,553,000.00 | 136,446,000.00 |
| Other Current Liabilities | N/A | N/A | 9,888,000.00 | 12,702,000.00 | 22,697,000.00 |
| Line item in (sek) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue From Contracts With Customers | 184,829,000.00 | 874,000.00 | 229,347,000.00 | 802,879,000.00 |
| Other Income | 4,385,000.00 | 2,501,000.00 | 259,000.00 | 2,862,000.00 |
| Profit Loss From Operating Activities | -28,019,000.00 | -379,720,000.00 | -524,456,000.00 | -421,943,000.00 |
| Finance Income | 926,000.00 | 547,000.00 | 20,336,000.00 | 50,195,000.00 |
| Finance Costs | 5,408,000.00 | 56,978,000.00 | 9,253,000.00 | 37,669,000.00 |
| Profit Loss Before Tax | -32,501,000.00 | -436,151,000.00 | -513,373,000.00 | -409,417,000.00 |
| Income Tax Expense Continuing Operations | 77,000.00 | 360,000.00 | -3,836,000.00 | 2,851,000.00 |
| Profit (loss) | -32,578,000.00 | -436,511,000.00 | -509,537,000.00 | -412,268,000.00 |
| Profit Loss Attributable To Owners Of Parent | -32,578,000.00 | -433,494,000.00 | -500,293,000.00 | -412,268,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | -3,017,000.00 | -9,244,000.00 | 0.00 |
| Line item in (sek) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | -32,578,000.00 | -436,511,000.00 | -509,537,000.00 | -412,268,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 2,308,000.00 | 15,465,000.00 | 66,676,000.00 | 61,260,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 0.00 | 0.00 | -949,000.00 | -2,758,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 2,308,000.00 | 15,465,000.00 | 66,676,000.00 | 61,260,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 325,000.00 | 393,000.00 | 5,432,000.00 | 35,252,000.00 |
| Interest Received Classified As Operating Activities | N/A | 926,000.00 | 1,912,000.00 | 102,000.00 | 3,553,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 528,000.00 | 3,949,000.00 | 7,392,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -71,011,000.00 | -309,181,000.00 | -461,588,000.00 | -311,354,000.00 |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | N/A | 0.00 | 172,602,000.00 | 0.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 118,000.00 | 0.00 | 6,588,000.00 | 2,512,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 16,066,000.00 | 0.00 | 16,066,000.00 | 0.00 |
| Cash Flows From Used In Investing Activities | N/A | -18,072,000.00 | -172,607,000.00 | -24,340,000.00 | -5,144,000.00 |
| Payments From Changes In Ownership Interests In Subsidiaries | N/A | 0.00 | 82,172,000.00 | 49,303,000.00 | 0.00 |
| Proceeds From Issuing Shares | N/A | 210,317,000.00 | 891,388,000.00 | 324,000,000.00 | 0.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | N/A | 0.00 | 0.00 | 236,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 1,652,000.00 | 3,972,000.00 | 5,575,000.00 | 9,615,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 198,835,000.00 | 768,558,000.00 | 435,162,000.00 | 575,990,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 109,752,000.00 | 286,770,000.00 | -50,766,000.00 | 259,493,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -2,387,000.00 | -44,006,000.00 | 9,969,000.00 | 34,094,000.00 |
| Cash and cash equivalents | 646,175,000.00 | 753,540,000.00 | 996,304,000.00 | 955,507,000.00 | 1,249,094,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 03.07.23 | Elmar Schnee | Other | Buy | SEK 1,092,824.52 |
| 28.12.22 | RENÉE AGUIAR LUCANDER | Other | Other | SEK 0.00 |
| 20.12.22 | RENÉE AGUIAR LUCANDER | Other | Other | SEK 14,527,500.00 |
| 20.12.22 | RENÉE AGUIAR LUCANDER | Other | Sell | SEK 13,448,750.00 |
| 20.12.22 | Katayoun Fatemeh Welin-Berger | Other | Sell | SEK 6,028,750.00 |
| 20.12.22 | Katayoun Fatemeh Welin-Berger | Other | Other | SEK 4,842,500.00 |
| 20.12.22 | Fredrik Johansson | Other | Sell | SEK 4,173,750.00 |
| 20.12.22 | Fredrik Johansson | Other | Other | SEK 3,725,000.00 |
| 20.12.22 | Frank Bringstrup | Other | Other | SEK 558,750.00 |
| 20.12.22 | Katayoun Fatemeh Welin-Berger | Other | Other | SEK 0.00 |
SE0010441584
LEI549300PVPZO8TNT76B58
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.